Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients

Nanobiotix NBTX announced updated data from phase 1 Study 1100 of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell carcinoma that is resistant to prior immunotherapy.
Reported data included 28 patients, with 21 evaluable for early signs of efficacy.
Treatment remained feasible and well-tolerated.
Objective reduction from baseline in target lesions was observed in 71.43% of evaluable patients (15/21).
42.86% of evaluable patients (9/21) showed objective reduction greater than 30%.
Related: Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial.
71.43% of evaluable patients (15/21) had cancer resistant to prior anti-PD-1 exposure, and tumor regression was observed in 66.66% of these patients (10/15).
As of the data cutoff, systemic disease control was durable and sustained for over 6 months in 38.10% of evaluable patients (8/21). The delayed objective reduction has been observed in several patients, suggesting the potential for anti-cancer immune activity over time.
The company plans to submit a registrational phase 3 protocol for evaluating RT-activated NBTXR3 plus anti-PD-1 in patients with LRR or R/M HNSCC resistant to anti-PD-1 to the FDA in Q1 of 2023.
Price Action: NBTX shares closed at $3.80 on Wednesday.